Clinical trial
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With…
NCT00003125 · Georgetown University, Other · Completed
Key facts
| NCT number | NCT00003125 |
|---|---|
| Title | Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors |
| Official title | A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 and GM-CSF in Patients With CEA Expressing Tumors |
| Lead sponsor | Georgetown University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | ALVAC-CEA vaccine, aldesleukin, sargramostim, vaccinia-CEA vaccine |
| Enrollment | 24 |
| Start date | Jan 1, 1998 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Apr 14, 2004 |
| Last update posted | Mar 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: